首页> 外文期刊>Peritoneal dialysis international: Journal of the International Society for Peritoneal Dialysis >Similar peritonitis outcome in CAPD and apd patients with dialysis modality continuation during peritonitis.
【24h】

Similar peritonitis outcome in CAPD and apd patients with dialysis modality continuation during peritonitis.

机译:在腹膜炎期间持续透析方式的CAPD和apd患者中,腹膜炎的预后相似。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: As few data exist on treatment of peritonitis in patients on automated peritoneal dialysis (APD), and as pharmacokinetics of several antibiotics are reported to be unfavorable in APD, some favor switching to continuous ambulant PD (CAPD) while treating APD-related peritonitis. We explored whether treating peritonitis with patients continuing their usual PD modality had an effect on outcome. METHODS: We performed a retrospective analysis of the 508 episodes of PD-associated peritonitis seen in 205 patients in our center from January 1993 to January 2007. During this period, the standard initial therapy for PD-related peritonitis was a combination of intraperitoneal gentamicin and rifampicin. RESULTS: There was no difference in cure rate between CAPD and APD groups. Likewise, initial and maximal leukocyte counts in the PD fluid (PDF), relapse rates, catheter removal rates, and death during treatment of peritonitis were similar in the CAPD and APD groups. Median (interquartile range) duration of elevated leukocyte count in PDF was longer in APD: 5.0 (3.0 - 9.0) days versus 4.0 (2.5 - 7.0) days in CAPD (p <0.001). APD patients were treated with antibiotics longer than CAPD patients: 16.0 (12.5 - 21.0) versus 15.0 (12.0 - 18.0) days (p = 0.036). Also, after correction for possible confounders, odds ratios for death and for the combined end point death or catheter removal showed no difference when patients treated for peritonitis stayed on their own modality. CONCLUSION: Regarding rate of relapse, mortality, or the combined end point mortality plus catheter removal, we found no difference between CAPD and APD patients continuing their own PD modality during treatment of PD-related peritonitis. Intermediate end points such as duration of elevated PDF leukocyte count and duration of antibiotic treatment were longer in APD patients.
机译:背景:由于很少有关于通过自动腹膜透析(APD)进行的患者腹膜炎治疗的数据,并且据报道,几种抗生素对APD的药代动力学不利,因此一些人倾向于在治疗APD相关性腹膜炎时改用连续性可移动PD(CAPD) 。我们探讨了继续接受常规PD方式的患者治疗腹膜炎是否对预后产生影响。方法:我们对1993年1月至2007年1月在我们中心的205例患者中发生的PD相关性腹膜炎的508例发作进行了回顾性分析。在此期间,PD相关性腹膜炎的标准初始治疗是腹膜内给予庆大霉素和利福平。结果:CAPD组与APD组之间治愈率无差异。同样,CAPD和APD组腹膜炎治疗期间PD液(PDF)的初始和最大白细胞计数,复发率,导管去除率和死亡相似。 PDF中白细胞计数升高的中位数(四分位数范围)持续时间在APD中更长:5.0(3.0-9.0)天,而在CAPD中为4.0(2.5-7.0)天(p <0.001)。 APD患者的抗生素治疗时间比CAPD患者更长:16.0(12.5-21.0)天对15.0(12.0-18.0)天(p = 0.036)。同样,在校正可能的混杂因素之后,当接受腹膜炎治疗的患者采用自己的方式时,死亡的比值比以及终点死亡或导管拔除的比值比也没有差异。结论:关于复发率,死亡率或终点死亡率加导管移除的总和,我们发现CAPD和APD患者在PD相关性腹膜炎治疗期间继续自己的PD方式之间没有差异。 APD患者的中间终点(如PDF白细胞计数升高的持续时间和抗生素治疗的持续时间)较长。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号